Biochip for predicting treatment effect of antidepressant and application

Abstract

The invention relates to a biochip, in particular to the biochip for predicting the treatment effect of an antidepressant and an application. The biochip for predicting the treatment effect of the antidepressant consists of a carrier and a bioprobe and is characterized in that the bioprobe comprises any one kind or several kinds of materials with the sequence from Seq NO: 1 to 20, and the tail ends of the sequences are modified through fluorescence labels. Through the biochip technology, the treatment effect of the antidepressant on patients can be predicted in an early period according to genetic gene features (single nucleotide polymorphism) of the patients from aspects such as the medicine species, the sexes of the patients receiving the treatment, the putative effect taking time point of medicine, the possibly generated adverse effect and the like, so clinic doctors can be guided to make and implement individualized treatment schemes.

Description

technical field [0001] The invention relates to a biological chip, in particular to a biological chip for predicting the treatment effect of an antidepressant and its application. Background technique [0002] Depression (Major depression disorder, MDD) is an affective disorder mental disease, mainly manifested as persistent depression, slow thinking and decreased will, often accompanied by cognitive impairment, behavioral disorder and physical symptoms. The lifetime prevalence rate is 10% to 20%, and the suicide rate is as high as 10% to 25%. The mental disability caused by depression has brought heavy mental and economic burdens to patients, families and society. Behaviors such as self-injury and suicide are even more harmful, and many patients have recurrent disease courses. Therefore, it is effective, standardized, and full-course antidepressant The importance of treatment cannot be overstated. [0003] At present, various new antidepressants represented by selective 5...

AI Technical Summary

Problems solved by technology

However, the individual differences in antidepressant treatment are very significant, some patients have serious adverse reactions, 30% to 50% of patients have no significant treatment effect, and 20% become treatment-resistant depression; moreover, the application of antidepressant drugs immediately leads to synaptic cleft 5-HT The / NE level increases, and the drug concentration in the brain remains stable at an effective level after 1 week of administration, but it usually takes 2 to 3 weeks for the clinical effect to take effect, and it takes more than 4 to 6 weeks for the full effect, and some patients stop early due to adverse reactions Drug therapy, resulting in an increased rate of early relapse and a markedly increased risk of suicide during the course of the disease

Significant differences in clinical efficacy of antidepressants and difficulties in early prediction of efficacy caused by delayed onset are extremely common and prominent clinical problems that need to be resolved urgently!